Repatha reduces CV events in patients who had PCI but no heart attack or stroke

In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced risk for major adverse CV events compared with placebo, according to new data from the VESALIUS-CV trial. As Healio previously reported, in the main results of VESALIUS-CV, the PCSK9 inhibitor evolocumab (Repatha, Amgen) lowered risk for major adverse CV events by

Raccontata dahealio.com